key: cord-0744873-7clfl5br authors: Nannan, Shi; Lanping, Guo; Wei, Wang; Yongyue, Xian; Yingying, Chen; Jing, Guo; Chunyan, Xu; Bei, Yan; Yang, Chen; Gang, Wang; Xiaodong, Cong; Luxing, Leng; Xiaolei, Xie; Dongxu, Li; Ming, Xu; Bing, Wang; Guoju, Dong; Zhenqi, Zhou; Jing, Li; Li, Zhang; Wenliang, Lv; Suping, Chen; Jianxin, Jiang; Cheng, Lv; Qing, Miao; Hao, Li; Jian, Wang; Huaxin, Shi; Bin, Li; Yongjun, Bian; Haoning, Zhu; Lijie, Hu; Wensheng, Qi; Jinliang, Yang; Jiaheng, Shi; Zhan, Shi; Renbo, Chen; Li, Li; Jia, Liu; Yibai, Xiong; Yaxin, Tian; Bin, Liu; Luqi, Huang title: Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: a non-randomized controlled trial date: 2020-10-08 journal: Phytomedicine DOI: 10.1016/j.phymed.2020.153367 sha: 17f3661470bab1be9cdada1f4d2eab8e487baf57 doc_id: 744873 cord_uid: 7clfl5br Background Treatments for coronavirus disease 2019 (COVID-19) are limited by suboptimal efficacy. Methods From January 30, 2020 to March 23, 2020, we conducted a non-randomised controlled trial, in which all adult patients with laboratory-confirmed COVID-19 were assigned to three groups non-randomly and given supportive treatments: Group A, Lopinavir-Ritonavir; Group B,Huashi Baidu Formula(a Chinese medicineformula made by the China Academy of Chinese Medical Sciences to treatCOVID-19, which is now in the clinical trial period) and Lopinavir-Ritonavir; and Group C, Huashi Baidu Formula. The use of antibiotics, antiviruses, and corticosteroids was permitted in Group A and B. Traditional Chinese medicine injections were permitted in Group C. The primary outcomes were clinical remission time (interval from admission to the first time the patient tested negatively for novel coronavirus or an obvious improvement was observed from chest CT) and clinical remission rate (number of patients whose clinical time was within 16 days/total number of patients) Results A total of 60 adult patients with COVID-19 were enrolled at sites in Wuhan, China, and the sample size of each group was 20. In Groups A, B and C, the clinical remission rates were95.0%(19/20), 100.0%(20/20) and 100.0%(20/20), respectively. Compared with Groups A and B, the clinical remission time of Group C was significantly shorter (5.9 days vs. 10.8 days, P < 0.050; 5.9 days vs. 9.7 days, P < 0.050). There was no significant difference among Groups A, B, and C in terms of the time taken to be released from quarantine. The clinical biochemical indicators and safety indexes showed no significant differences among the three groups. Conclusions Our findings suggest that Lopinavir-Ritonavir has some efficacy in the treatment of COVID-19, and the Huashi Baidu Formula might enhance this effect to an extent. In addition, superiority was displayed in the treatment of COVID-19 through a combination of the Huashi Baidu Formula and traditional Chinese medicine injection. In future, well-designed prospective double-blinded randomised control trials are required to confirm our findings. In late December 2019, a cluster of acute respiratory illnesses, now known as novel coronavirus pneumonia (NCP), occurred in Wuhan, Hubei Province, China. [1] The NCP rapidly spread worldwide, posing a severe threats to international public health. [2, 3] Subsequebtly, the World Health Organization (WHO) declared a Public Health Emergency of International Concern over the global outbreak of coronavirus disease 2019 in January 31, 2020. Some COVID-19 infections can be severe, particularly in older adults with underlying medical conditions. [4, 5] The disease onset may result in progressive respiratory failure due to alveolar damage, and even death. China is currently directly affected by the COVID-19 pandemic. It is believed that vaccines and medicines can be developed to control and prevent this disease. However, the development of vaccines is usually hysteretic and currently there are no clinically confirmed specific antiviral treatments for COVID-19. Treatments used at present are generally supportive. Therefore, it is necessary to urgently conduct clinical trials of medicines to identify suitable treatments for COVID-19. Previous studies have indicated thatthe combination of lopinavir and ritonavir may be beneficial for patients infected with SARS-CoV and MERS-CoV. [6, 7] However, corticosteroids have not been found to reduce the mortality of SARS-CoV and MERS-CoV infection based on the WHO interim guidance. [7] Chinese herbal medicine (CHM) has been used to control infectious diseases for thousands of years, and previous studies suggest that combining Chinese with Western medicine is useful in the treatment of SARS caused by coronavirus infection. [8, 9] CHM is a potentially effective method for controlling the newly emerged NCP. From the perspective of CHM, COVID-19 belongs to the category of 'epidemic disease', and the total pathogenesis can be summarised as dampness, poison, blood stasis and deficiency. [10] . CHM treatment focuses on mobilising the body's own disease resistance, and has unique advantages in improving clinical symptoms, reducing complications, and improving quality of life. A variety of Chinese medicine treatment compounds are recommended in the Chinese 6 th edition guidelines. It is highly feasible to identify and develop active components against novel coronaviruses from these compounds. In this study, we conducted a non-randomized controlled trial (NRCT) at Jinyintan Hospital in Wuhan. We aimed to evaluate the efficacy and safety of CHM and Lopinavir-Ritonavir treatment in adult patients with COVID-19. A prospective, single-center, NRCT design was conducted from January 30 to March 23, 2020 at Jingyintan Hospital in Wuhan, Hubei province, China. All treatments were generally conducted, and baseline symptoms of patients with COVID-19 were assessed, within 24 h of enrolling. When the respiratory symptoms obviously improved and two consecutive novel coronavirus nucleic acid tests showed negative results (the interval between sampling was a minimum of one day), patients were discharged from quarantine. The patients were non-randomly divided into three treatment groups with the patients' informed consent: (1) Group A: Lopinavir-Ritonavir, n = 20; (2) Group B: Huashi Baidu Formula (a Chinese medicine formula made by the China Academy of Chinese Medical Sciences to treat COVID-19, which is now in the clinical trial periodformula) and Lopinavir-Ritonavir, n = 20; and (3) Group C: Huashi Baidu Formula, n = 20. The use of antibiotics, antiviruses, and corticosteroids was permitted in Groups A and B. Traditional Chinese medicine injections were permitted in Group C. The detailed treatments of the three groups were as follows: Lopinavir-Ritonavir (500 mg twice daily, orally), antibiotics (such as cefoperazone, 2 g twice daily, intravenous injection; moxifloxacin hydrochloride tablets, 0.4 g once daily, orally), corticosteroids (such as methylprednisolone, 40 mg once daily, intravenous injection; prednisone, 30 mg once daily, orally), antiviruses (such as arbidol capsule, 0.2 g three times daily, orally), Huashi Baidu Formula (137 g twice daily, orally), ShenMai injection (60 mL once daily, intravenous injection), XiYanPing injection (100 mg twice daily, intravenous injection), and XueBiJing injection (100 mLtwice daily, intravenous injection). All groups received supportive therapy, including oxygen inhalation, symptomatic treatment and/or immunoglobulin intravenous injection and/or serum albumin intravenous injection, and treatment for basic diseases. The test population was clinically diagnosed with COVID-19 in accordance with the diagnostic criteria for the diagnosis and treatment of NCP (trial edition 4) issued by the National Health Commission of the People's Republic of China and the National Administration of Traditional Chinese Medicine. Male and non-pregnant/non-lactating female patients aged 18 to 85 years were eligible if they met the diagnostic criteria for COVID-19 in the diagnosis and treatment of novel coronavirus pneumonia (trial edition 4). Exclusion criteria included patients infected with critically severe COVID-19, patients who were over 15 days of symptom onset or who had severe primary respiratory system diseases, patients who have difficulty with oral and nasal feeding, patients with serous basic diseases, including malignant tumours, mental illness, and other malignant diseases, patients who had continuously used of immunosuppressants or received organ transplants within the past six months, and those who had an allergic constitution or were allergic to Huashi Baidu Formula. The withdrawal criteria included patients who underwent severe adverse events and could not continue to take medicines as primary groups during the observation period, those whose condition worsened or resulted in death, and those who were transferred to another hospital, left the present hospital, or received a confirmed misdiagnosis. Written informed consent was obtained from all participants. The trial was designed by the China Centre for Evidence-Based Traditional Chinese Medicine and implemented in partnership with Jinyintan Hospital in Wuhan, and was supported by grants from the National Key R&D Program of China (No. 2020YFC0841500) and the China Academy of Chinese Medical Sciences SARS-CoV-2. The members of the writing group were responsible for the collection and analysis of the data and for the preparation of the manuscript. All details regarding trial design, conduct, and analyses can be found in the protocol (No. ChiCTR2000029400/ChiMCTR2000002940). The primary outcomes were clinical remission time (interval from admission to the first time the patient tested negatively for novel coronavirus or an obvious improvement was observed from chest CT) and clinical remission rate (number of patients whose clinical time was within 16 days/total number of patients). The secondary outcomes were the time of release from quarantine (interval from admission to discharge), the rate of being released from quarantine (number of patients discharged within 16 days/ total number of patients), and clinical biochemical indicators. Other outcomes were safety indexes, such as liver function (ALT, AST), kidney function (creatinine), and myocardial damage. Continuous variables were described using mean ± standard deviation or median ± interquartile range (IQR). In addition, the clinical remission time and time of release from quarantine were portrayed by Kaplan-Meier plots and compared with the log-rank test. The count data were expressed as the number of cases or percentages. Differences between groups were assessed using analysis of variance or Welch's variance analysis for continuous variables and the Chi-square test or Fisher's exact test for categorical variables. Comparisons were made between baselines and outcomes of groups using paired t-tests. SPSS Ver. 21.0 (IBM Corp, Armonk, NY, USA) was used for all statistical analyses. For all comparisons, differences were tested with two-tailed tests, and P < 0.05 was considered statistically significant. A total of 111 patients were evaluated for eligibility, and 44 patients were excluded according to the inclusion and exclusion criteria. The remaining 67 patients were assigned by non-randomized grouping, of which 22 patients were assigned to Group A, 23 patients to Group B, and 22 patients to Group C. In Group A, one patient refused Lopinavir-Ritonavir treatment, and one patient died in hospital, In Group B, three patients refused Lopinavir-Ritonavir treatment, and in Group C, two patients refused traditional Chinese medicine treatment (flow program). In the study, 66.7% (40/60) of patients were male and 33.3% (20/60) were female. The median age of the patients was 54.5 years (IQR, 45.0 to 64.8 years). The most common chronic medical illnesses were cardiovascular and cerebrovascular diseases, followed by endocrine system disease. Group B had a lower proportion of males than the other two groups. Except for lactate dehydrogenase and creatine kinase, no other major differences in age, chronic medical illness history, number of patients with a fever, and physical and chemical indexes of the three groups were observed at baseline (P > 0.050) ( Table 1, Table 2 ). (Table 3 ). According to the log-rank test, there was a significant difference among the three groups (P = 0.013). Pairwise comparisons were conducted using the LSD method, and statistical differences were identified between Group C and Group A as well as Group C and Group B (P < 0.050) ( Table 3 ), suggesting that the curative effect of the Huashi Baidu Formula was better than that of the other two treatments. The time taken before being released from quarantine was 16.7 ± 6.6 days in Group A, 15.0 ± 6.6 days in Group B, and 14.5 ± 7.9 days in Group C. There were no statistical differences (P > 0.050) among the three groups ( Table 3 ). The rates of release from quarantine in Groups A, B, and C were 60.0% The number and proportion of patients with improvements in biochemical indicators are described inTable 2. The recovery rate of lactate dehydrogenase in Group B and C was 71.4% (5/7), while in Group A was 60.0% (9/15).The recovery rate of leukocytes in Group A was 100.0% (3/3), while in Group B and C was 50.0% (3/6) and 75.0% (3/4) respectively. In terms of creatine kinase, the recovery rate was 77.8% (7/9) in Group A, 57.1% (4/7) in Group B and 50.0% (3/6) in Group C. In terms of lymphocytes and interleukin 6, the recovery rate in Group C (83.3%[5/6] and 40.0% [4/10]) was significantly higher than in Group A and B. A paired t-test was used for comparisons before and after treatments, and the results (Table 4) showed that there were significant differences in neutrophil, lymphocyte, albumin, glutamic-oxalacetic transaminase, serum creatinine, creatine kinase, lactate dehydrogenase, and C-reactive protein levels as well as in prothrombin, and activated partial thrombin activity times both before and after treatment in Group A (P < 0.050). Significant differences were observed in haemoglobin, albumin, total bilirubin, creatine kinase, lactate dehydrogenase, interleukin-6, and C-reactive protein level as well as prothrombin and activated partial thrombin activity times both before and after treatment in Group B (P < 0.050). In Group C, significant differences were observed in neutrophil, haemoglobin, albumin, glutamic-oxalacetic transaminase, creatine kinase, lactate dehydrogenase, interleukin-6, and C-reactive protein levels both before and after treatment (P < 0.050). In this study, the safety indexes were biochemical indicators (normal / abnormal). There was no significant difference among the three groups or within the groups in terms of the safety indexes at baseline (P > 0.050). After different treatments, the proportion of patients with abnormal creatinine in Group A increased significantly, while that in Group C increased slightly and in Group B did not change, indicating that Group B treatment was marginally safer in terms of renal function than those of the other two groups. Besides, Glutamic-pyruvic and oxalacetic transaminases could reflect liver function, and there was no statistical difference among the three groups (P > 0.050). The proportion of patients with these two abnormal indicators in Group A and C decreased, while in Group B increased. In addition, the proportion of patients with abnormal creatine kinase in the three groups decreased, which suggested that the three treatments exhibited no significant harm on cardiac function. In total, the patients in the three groups suffered no obvious adverse events (Table 5 ). To date, no targeted vaccine or specific drugs have been developed for the prevention or treatment of NCP. Based on previous experiences relating to the treatment of SARS, MERS, or other novel influenza viruses, Lopinavir/Ritonavir, Redesivir, nucleoside analogues, neuraminidase inhibitors, and Abidor have been used in the clinical treatment of patients with COVID-19, but their clinical efficacy and safety need to be confirmed in further clinical trials. [11] Recent studies [12] have identified Redesivir as a potential treatment for NCP. Currently, Phase 3 clinical drug trials have been launched in China, but the above studies are in the exploratory phase. For the treatment of inflammation, corticosteroids have been used frequently for severe patients with severe cases of SARS-CoV, [13, 14] MERS-CoV, [15, 16] and COVID-19. However, current evidence for SARS and MERS suggests that corticosteroids have no effect on mortality, but rather delay viral clearance. In the present study, the median time of release from quarantine after Lopinavir-Ritonavir treatment was 15.0 (13.0-19.0) days, which is a similar result to that in a previous study (14 (12) (13) (14) (15) (16) (17) ) days), [24] indicating that the therapeutic effect of Lopinavir-Ritonavir treatment is relatively consistent. In Group A, In Group C, we adopted the method of CHM syndrome differentiation, and administered individual treatment plans according to each patient's condition, including oral Chinese medicine decoction and Chinese patent medicine, and some patients were administered traditional Chinese medicine injections. In addition, some patients used a combination of CHM decoction and injection at the early stage of admission, which was inconsistent with the use of CHM injection recommended only for severe and critically ill patients in the national program. However, this study found that the combination of the Several patients in this study had abnormal creatinine levels after Lopinavir-Ritonavir treatment. The number of patients with abnormal glutamic-pyruvic and oxalacetic transaminase levels after the combination of Lopinavir-Ritonavir and Huashi Baidu Formula treatment also slightly increased. However, there was no significant difference in safety indexes between and within the groups (P > 0.05). Although one patient died during hospitalization in Group A, researchers determined that it was not related to the intervention. In total, none of the patient in the study experienced severe adverse events. LH is the corresponding author, others are joint first authors. HS and LH obtained funding. HS, LH, CL, ZS, RC, LL, JL, YX, YT and BL designed the study. WW, JG, BY, YC, LL, DL, YX, YC, CX, GW, XC and XX collected the data. WL, SC, JW, YB, WQ, JY and JS were involved in data cleaning and verification. MX, BW, GD, JL, LZ, QM, HL, BL, HZ and JJ analyzed the data. NS and LG drafted the manuscript. LQ contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content. All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy. 6 LIMITATIONS AND STRENGTHS There were several limitations to this study. First, the trial was non-randomized and unblinded, thus, findings of statistical tests and P-values should be interpreted with caution, and non-significant P-values did not necessarily rule out differences between the three groups. Second, due to the small sample size and single centre site, it was difficult to assess host risk factors for disease severity and mortality using multivariable adjusted methods. A larger randomised control trial would assist in defining the clinical epidemiological characteristics and risk factors. Third, the interventions in this study were not completely in accordance with the three groups. Further studies in outpatient, primary care, or community settings are needed to follow-up the prognosis and recovery of patients. The present study also has some strengths. First, it is one of few clinical control trials to explore the efficacy and safety of CHMs and western medicines in COVID-19 treatment. Second, we used many indicators to describe the efficacy and safety of the medicines, such as clinical remission rate, clinical remission time, and rate of release from quarantine, making the outcomes more diversified. Lopinavir-Ritonavir had an effect as a treatment for COVID-19, and this effect was enhanced when All authors declare that no support from any organization for the submitted work; no financial relationships with any organization that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. The authors declare no competing interests. Scientific background and explanation of rationale 3 2b Specific objectives or hypotheses 3 Description of trial design (such as parallel, factorial) including allocation ratio 3-4 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons - Eligibility criteria for participants 4 4b Settings and locations where the data were collected 3-4 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 4 Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 4 6b Any changes to trial outcomes after the trial commenced, with reasons -Sample size 7a How sample size was determined -7b When applicable, explanation of any interim analyses and stopping guidelines -Randomisation: Sequence generation 8a Method used to generate the random allocation sequence -8b Type of randomisation; details of any restriction (such as blocking and block size) -Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned -Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions -Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing -14 outcomes) and how 11b If relevant, description of the similarity of interventions -Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 4-5 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 5 Participant flow (a diagram is strongly recommended) 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 5 13b For each group, losses and exclusions after randomisation, together with reasons 5 Recruitment 14a Dates defining the periods of recruitment and follow-up 3 14b Why the trial ended or was stopped -Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table file,1 Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 5 Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment. The New England journal of medicine Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS Is traditional Chinese medicine useful in the treatment of SARS? Phytotherapy research : PTR Understanding and Thinking of Novel Coronavirus Pneumonia in Trditinal Chinese Medicine Drug treatment options for the 2019-new coronavirus (2019-nCoV) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. The Journal of pathology Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PloS one Treatment with interferon-α2b and ribavirin improves outcome in 36 Research progress on the pharmacological action and mechanism of Pogostemonis Herba Research progress on pharmacological action of Astragali radix Study progress on chemical constituents and pharmacological effects of Descurainiae Semen Lepidii Semen Research progress on pharmacologic experiments of Pinelliae Rhizoma Praeparatum Research progress on the chemical constituents and pharmacological effects of Tsaoko Fructus. Pharmacy And Clinics Of Chinese Materia Medical Reevaluation of the pharmacological effects of Atractylodis Rhizoma Pharmacological action and clinical application of Magnoliae Officinalis Cortex. Chinese Community Doctors Research Progress on Chemical Constituents and Clinical Application of Ephedra Plants New research progress on the chemical constituents and pharmacological effects of Rhei Radix et Rhizoma Writing -Original Draft Formal analysis, Guo Jing: Formal analysis, Yan Bei: Formal analysis, Chen Yang: Formal analysis Title and abstract 1a Identification as a randomised trial in the title 1 1bStructured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2